COSCIENS Biopharma Statistics
Total Valuation
CSCI has a market cap or net worth of $13.38 million. The enterprise value is -$12.29 million.
Important Dates
The next estimated earnings date is Monday, November 11, 2024, before market open.
| Earnings Date | Nov 11, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
CSCI has 3.12 million shares outstanding. The number of shares has increased by 7.69% in one year.
| Shares Outstanding | 3.12M |
| Shares Change (YoY) | +7.69% |
| Shares Change (QoQ) | +82.90% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 3.43M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.36, with a Debt / Equity ratio of 0.06.
| Current Ratio | 3.36 |
| Quick Ratio | 2.95 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2,253.00 |
Financial Efficiency
Return on equity (ROE) is -65.92% and return on invested capital (ROIC) is -39.37%.
| Return on Equity (ROE) | -65.92% |
| Return on Assets (ROA) | -23.34% |
| Return on Capital (ROIC) | -39.37% |
| Revenue Per Employee | $409,583 |
| Profits Per Employee | -$1.52M |
| Employee Count | 12 |
| Asset Turnover | 0.10 |
| Inventory Turnover | 0.57 |
Taxes
| Income Tax | -573,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -38.02% in the last 52 weeks. The beta is 2.27, so CSCI's price volatility has been higher than the market average.
| Beta (5Y) | 2.27 |
| 52-Week Price Change | -38.02% |
| 50-Day Moving Average | 3.88 |
| 200-Day Moving Average | 6.33 |
| Relative Strength Index (RSI) | 41.02 |
| Average Volume (20 Days) | 3,510 |
Short Selling Information
The latest short interest is 6,774, so 0.22% of the outstanding shares have been sold short.
| Short Interest | 6,774 |
| Short Previous Month | 9,359 |
| Short % of Shares Out | 0.22% |
| Short % of Float | 0.20% |
| Short Ratio (days to cover) | 1.64 |
Income Statement
In the last 12 months, CSCI had revenue of $4.92 million and -$18.23 million in losses. Loss per share was -$13.94.
| Revenue | 4.92M |
| Gross Profit | 4.01M |
| Operating Income | -18.02M |
| Pretax Income | -18.05M |
| Net Income | -18.23M |
| EBITDA | -17.99M |
| EBIT | -18.02M |
| Loss Per Share | -$13.94 |
Full Income StatementBalance Sheet
The company has $27.80 million in cash and $1.69 million in debt, giving a net cash position of $26.12 million or $8.38 per share.
| Cash & Cash Equivalents | 27.80M |
| Total Debt | 1.69M |
| Net Cash | 26.12M |
| Net Cash Per Share | $8.38 |
| Equity (Book Value) | 26.23M |
| Book Value Per Share | 8.57 |
| Working Capital | 23.31M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$19.27 million and capital expenditures -$655,000, giving a free cash flow of -$19.92 million.
| Operating Cash Flow | -19.27M |
| Capital Expenditures | -655,000 |
| Free Cash Flow | -19.92M |
| FCF Per Share | -$6.39 |
Full Cash Flow StatementMargins
| Gross Margin | 81.67% |
| Operating Margin | -366.71% |
| Pretax Margin | -382.56% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -731.63% |